Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.42 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225551 | 0.84 | KIF11 (0.55) | KIF11KEAP1HPGDKDM4EALDH1A1 | |
| SCHEMBL183564 | 0.80 | KEAP1 (0.57) | KIF11KEAP1HPGDKDM4EALDH1A1 | |
| SCHEMBL3140241 | 0.80 | KIF11 (0.63) | KIF11KEAP1HPGDKDM4EALDH1A1 | |
| SCHEMBL873846 | 0.80 | KEAP1 (0.75) | KIF11KEAP1HPGDKDM4EALDH1A1 | |
| SCHEMBL31041151 | 0.80 | KIF11 (0.79) | KIF11KEAP1HPGDKDM4EALDH1A1 | |
| Lithium SCHEMBL31041154 | 0.78 | KIF11 (0.76) | KIF11KEAP1HPGDKDM4EALDH1A1 | |
| SCHEMBL27617811 | 0.78 | HPGD (0.54) | KIF11KEAP1HPGDKDM4EALDH1A1 | |
| SCHEMBL2183055 | 0.77 | PTGS2 (0.52) | — | |
| SCHEMBL3146438 | 0.76 | KMT2A (0.46) | KDM4ESMN1; SMN2CA1CA2NR3C2 | |
| SCHEMBL17200847 | 0.75 | ALDH1A1 (0.37) | ALDH1A1HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-111699189-A | Modulators of beta-3 adrenergic receptors useful for the treatment or prevention of heart failure and disorders associated therewith | 艾尼纳制药公司 | 2020-09-22 | — | — | CN | claimed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | claimed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | claimed |
| CN-105980386-A | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2016-09-28 | — | — | CN | claimed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | claimed |
| EP-2970307-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2015135094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2015-09-17 | — | — | WO | claimed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | 4SC AG (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
| EP-3962559-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | 4SC AG (DE) | 2021-04-22 | — | — | US | disclosed |
| US-20100074862-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | MAIER THOMAS | 2010-03-25 | — | — | US | disclosed |
| US-7666868-B2 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | 4SC AG (DE) | 2010-02-23 | — | — | US | disclosed |
| EP-1861365-B1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20080176848-A1 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | NYCOMED GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1861365-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | Nycomed GmbH (DE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097474-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | NYCOMED GMBH (DE) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | HDAC8, TLR8, TLR7 | KIF11 2131/4885KEAP1 1995/4885HPGD 742/4885 |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | KIF11 1672/4885KEAP1 447/4885HPGD 1427/4885 |
| US-20080176848-A1 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | HDAC1, H1-3, HDAC2 | KIF11 3139/4885KEAP1 1747/4885HPGD 477/4885 |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | HDAC7, HDAC1, HDAC11 | KIF11 2237/4885KEAP1 3312/4885HPGD 3820/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | KIF11 1672/4885KEAP1 447/4885HPGD 1427/4885 |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MUC1, FABP6 | KIF11 3980/4885KEAP1 166/4885HPGD 388/4885 |
| US-20100074862-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC2 | KIF11 4111/4885KEAP1 1632/4885HPGD 1247/4885 |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | HDAC1, HDAC3, HDAC11 | KIF11 770/4885KEAP1 1799/4885HPGD 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.